Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform
PLOS One · 2026
DOI: 10.1371/journal.pone.0342382 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS One, 2026. Verfasst von Hannah R Volkman und 23 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., New York, New York, United States of America. Hauptthemen laut MEDLINE: Hospitalization, COVID-19, SARS-CoV-2, COVID-19 Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc..
Abstract (Originalsprache)
Background
While multiple studies report that the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (BNT162b2 XBB vaccine) is effective in preventing COVID-19 hospitalisation and death, effectiveness beyond six months remains unexplored.
Methods
We extended our previous study of BNT162b2 XBB vaccine effectiveness (VE) to evaluate durability against JN.1-related hospitalisation up to 46 weeks since dose using the id.DRIVE platform across Europe. This multi-country, multi-centre test-negative case-control study assessed the effectiveness and durability of the BNT162b2 XBB vaccine in preventing JN.1-associated hospitalisation among adults with severe acute respiratory infection between October 2023 and August 2024. Each case was matched with up to four controls by symptom onset date and study site. Multivariable analyses were adjusted for symptom onset date, age, sex, number of chronic conditions, and influenza vaccination receipt.
Results
Among 827 test-positive cases and 2232 test-negative controls, protection against hospitalisation was sustained from two to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pfizer Inc., New York, New York, United States of America.
- P95 Clinical and Epidemiology Services, Leuven, Belgium.
- Microbiology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
- Hospital Universitari Germans Trias i Pujol, Carretera del Canyet, Badalona, Barcelona, Spain.
- Department of Internal Medicine III, Division of Infectious Diseases, University Hospital Ulm, Ulm, Germany.
- Centro Interuniversitario per la Ricerca sull'Influenza e le altre Infezioni Trasmissibili - IRCCS Policlinico San Martino Hospital, Genoa, Italy.
ORCID-Profile: Hannah R Volkman, Leonie de Munter, Thao M P Tran, Andrés Antón, Beate Grüner
Förderung
- Pfizer Inc.
Zitieren
APA
Volkman, H. R., de Munter, L., Nguyen, J. L., Tran, T. M. P., Mitratza, M., Marques, C., Choi, L., Valluri, S., Yang, J., Antón, A., Casas, I., Conde-Sousa, E., Drikite, L., Grüner, B., Icardi, G., Ten Kate, G. L., Martin, C., Mira-Iglesias, A., Orrico-Sánchez, A., …, & Bollaerts, K. (2026). Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform. PLOS One. https://doi.org/10.1371/journal.pone.0342382
Vancouver
Volkman HR, de Munter L, Nguyen JL, Tran TMP, Mitratza M, Marques C, et al. Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform. PLOS One. 2026. doi:10.1371/journal.pone.0342382
BibTeX
@article{Volkman2026,
author = {Volkman, Hannah R and de Munter, Leonie and Nguyen, Jennifer L and Tran, Thao M P and Mitratza, Marianna and Marques, Cátia and Choi, Laura and Valluri, Srinivas and Yang, Jingyan and Antón, Andrés and Casas, Irma and Conde-Sousa, Eduardo and Drikite, Laura and Grüner, Beate and Icardi, Giancarlo and Ten Kate, Gerrit Luit and Martin, Charlotte and Mira-Iglesias, Ainara and Orrico-Sánchez, Alejandro and Otero-Romero, Susana and Rohde, Gernot and Jodar, Luis and McLaughlin, John M and Bollaerts, Kaatje},
title = {Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0342382}
}
EUVIMED